Profile data is unavailable for this security.
About the company
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
- Revenue in CAD (TTM)1.51m
- Net income in CAD-367.12k
- Incorporated2017
- Employees--
- LocationWaverley Pharma Inc4-1250 Waverley StreetWINNIPEG R3T 6C6CanadaCAN
- Phone+1 (204) 928-7907
- Fax+1 (204) 453-1370
- Websitehttps://www.waverleypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Many Bright Ideas Technologies Inc | 0.00 | -69.34k | 229.04k | -- | -- | -- | -- | -- | -0.004 | -0.004 | 0.00 | -0.0167 | 0.00 | -- | -- | -- | -741.19 | -272.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.88 | -- | -- | -- |
| Vaxil Bio Ltd | 0.00 | -76.00k | 557.76k | -- | -- | 0.575 | -- | -- | -0.0277 | -0.0256 | 0.00 | 0.2435 | 0.00 | -- | -- | -- | -10.17 | -48.47 | -10.82 | -73.00 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.92 | -- | -- | -- |
| Waverley Pharma Inc | 1.51m | -367.12k | 810.00k | -- | -- | -- | -- | 0.538 | -0.0068 | -0.0068 | 0.0279 | -0.0437 | 0.9855 | 4.24 | 58.65 | -- | -24.03 | -38.03 | -- | -122.91 | 39.48 | 18.66 | -24.38 | -101.43 | 0.0382 | -1.64 | 3.74 | -- | 15.36 | -16.30 | 57.42 | -- | -- | -- |
